Neoadjuvant chemotherapy in advanced ovarian cancer: What kind of evidence is needed to convince US gynaecological oncologists?

Ignace Vergote
, Frederic Amant
, Karin Leunen

Research output: Contribution to journal › Editorial › Academic › peer-review

Original language	English
Pages (from-to)	1-2
Journal	Gynecologic oncology
Volume	119
Issue number	1
DOIs	https://doi.org/10.1016/j.ygyno.2010.08.011
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.ygyno.2010.08.011

Cite this

@article{82a839be54be4780888624fd65fc8b34,

title = "Neoadjuvant chemotherapy in advanced ovarian cancer: What kind of evidence is needed to convince US gynaecological oncologists?",

author = "Ignace Vergote and Frederic Amant and Karin Leunen",

year = "2010",

doi = "10.1016/j.ygyno.2010.08.011",

language = "English",

volume = "119",

pages = "1--2",

journal = "Gynecologic oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "1",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy in advanced ovarian cancer: What kind of evidence is needed to convince US gynaecological oncologists?

AU - Vergote, Ignace

AU - Amant, Frederic

AU - Leunen, Karin

PY - 2010

Y1 - 2010

U2 - 10.1016/j.ygyno.2010.08.011

DO - 10.1016/j.ygyno.2010.08.011

M3 - Editorial

C2 - 20833283

SN - 0090-8258

VL - 119

SP - 1

EP - 2

JO - Gynecologic oncology

JF - Gynecologic oncology

IS - 1

ER -